Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
NCT02505269Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Massachusetts General Hospital. Started Aug 2015; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02505269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505269.